Search Results
Jul 29, 2026, 06:30 ET Entergy reports second quarter 2026 financial results
as well as higher compensation and benefits costs resulting from higher healthcare claims activity and the timing of the recognition of prescription drug rebates. The second quarter decrease was partially offset by lower bad debt expense. The year-to-date earnings decrease from higher Utility other
More news about: Entergy Corporation
Jul 29, 2026, 06:27 ET Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration
More news about: BioArctic
Jul 29, 2026, 06:00 ET Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.Amphastar's
More news about: Amphastar Pharmaceuticals, Inc.
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.Venous thromboembolismEvents
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.Venous thromboembolismEvents
More news about: AbbVie
Jul 29, 2026, 02:29 ET Photocure ASA: Results for the second quarter of 2026
long-term opportunities for Photocure's Cysview business remains the ongoing regulatory evolution in the United States. Following the U.S. Food and Drug Administration's response to the Karl Storz Citizen Petition earlier this year, the Agency confirmed plans to initiate the proposed reclassification
More news about: Photocure
Jul 29, 2026, 02:25 ET Photocure ASA: Results for the second quarter of 2026
long-term opportunities for Photocure's Cysview business remains the ongoing regulatory evolution in the United States. Following the U.S. Food and Drug Administration's response to the Karl Storz Citizen Petition earlier this year, the Agency confirmed plans to initiate the proposed reclassification
More news about: Photocure
Jul 29, 2026, 00:00 ET Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use DisorderAURORA, Colo., July
More news about: University of Colorado Anschutz
Jul 28, 2026, 19:31 ET Dr. Gary Lawton Yale-Trained Plastic Surgeon: New Non-Opioid Pain Medication for Recovery Protocols
non-opioid drug class — into his postoperative pain management protocol for tummy tuck patients, including those undergoing tummy tucks as part of a combined mommy makeover with breast augmentation, breast lift, breast reduction, or implant revision surgery.Approved by the U.S. Food and Drug Administration
More news about: LAWTON PLASTIC SURGERY
Jul 28, 2026, 14:32 ET Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].
More news about: Glenmark Pharmaceuticals
Jul 28, 2026, 13:30 ET Icarus Wellness and Recovery Names Mallory Harris as Executive Director
Idaho residents age 12 or older had a substance use disorder in the past year, based on annual averages from 2021 through 2023. Idaho also recorded 337 drug-overdose deaths in 2024, according to the Idaho Department of Health and Welfare.Harris's leadership approach pairs established clinical practices
More news about: Icarus Wellness and Recovery
Jul 28, 2026, 12:34 ET Top 5 Gundry MD Polyphenol Dark Spot Diminisher Review: Where to Buy, What's Inside, and Does It Actually Work?
✝ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.*All individuals
More news about: Gundry MD
Jul 28, 2026, 12:30 ET New blood test for tuberculosis could reduce the spread of this top global infectious-disease killer
used in a real-world clinical setting," Dr. Pan said.Although sputum cultures remain essential for verifying TB and providing information about drug resistance, ESAT-6 holds promise as a practical tool for triaging patients in instances when sputum-based diagnostics are limited or delayed.Session
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
Jul 28, 2026, 12:26 ET Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products
These products focus on drugs and drug substances on the FDA short list, which are eligible for expedited IND review. Production is expected to begin within the next three to four months,
More news about: Vector Sciences & Therapeutics
Jul 28, 2026, 12:09 ET Get a Second Opinion Launches America's First Pre‑Prescription Intelligence Platform
can understand their full medication regimen before treatment begins. Each personalized Second Opinion report ranks available options, translates FDA Drug Label content into plain English, highlights risks and contraindications, and provides clear next‑step guidance based on a patient's unique non‑PII
More news about: Get A Second Opinion Inc.
Jul 28, 2026, 12:05 ET Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy
company pioneering Endoscopic Metabolic Restoration, today announced the successful treatment of the first U.S. patient in its U.S. Food and Drug Administration (FDA)-authorized Investigational Device Exemption (IDE) clinical trial evaluating the company's proprietary Proximal Intestinal Mucosal
More news about: Aqua Medical Inc.
Jul 28, 2026, 12:00 ET Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist
"Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for biomedical research, to Ono's drug discovery scientists.
More news about: Phylo, Inc.
Jul 28, 2026, 12:00 ET Vivid Dx Raises $15M to Help Hospitals Confront One of Modern Medicine's Most Urgent Threats: Drug-Resistant Infections
During that window, clinicians are forced to treat without complete information, often relying on broad-spectrum antibiotics that may not work against drug-resistant infections. This delay is a major public health issue: researchers estimate antimicrobial resistance (AMR) could contribute to
More news about: Vivid Dx
Jul 28, 2026, 11:32 ET Stephens Law Firm Earns 2 of Texas' 5 Largest Truck Accident Settlements, Texas' No. 1 Truck v. Car Settlement, No. 1 Settlements in Tarrant County
footageDriver qualification and hours-of-service recordsMaintenance and inspection recordsDispatch communicationsDrug and alcohol testing recordsCell phone recordsMuch of this evidence can disappear if it is not preserved shortly after the crash.About
More news about: Stephens Law
Jul 28, 2026, 11:28 ET Lupin Announces the Approval of Diazepam Injection, USP in the United States
(NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.
More news about: Lupin Pharmaceuticals, Inc.
Jul 28, 2026, 10:32 ET Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
demand for effective therapies and long-term disease management.Advancements in Pharmacological Therapies: The introduction of novel drug classes, including SGLT2 inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), soluble guanylate cyclase stimulators, and cardiac myosin activators,
More news about: DelveInsight Business Research, LLP
Jul 28, 2026, 10:30 ET Biopharmaceutical Process Analytical Technology Market worth $4.32 billion by 2031 - Exclusive Report by MarketsandMarkets™
[Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Software, Services], Inlet Type (LC-MS, GC-MS, ICP-MS, Other Inlet Types), Application (Omics, Drug Discovery, Food, Environmental), End User (Pharma, Biotech) - Global Forecast to 2031
More news about: MarketsandMarkets
Jul 28, 2026, 10:15 ET Antibody Therapeutics Market worth $597.1 billion by 2035 - Exclusive Report by MarketsandMarkets™
commercial foundation that dominated the market in 2025, while the industry increasingly expands into bispecific and multispecific antibodies, antibody–drug conjugates, antibody fragments, and other engineered formats. These next-generation modalities can combine multiple mechanisms, improve target selectivity,
More news about: MarketsandMarkets
Jul 28, 2026, 10:00 ET RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
catalyst for rare disease advocates who are ready to lead, build vibrant ecosystems, partner with industry, and advance drug development pipelines."For a decade, the Rare Drug Development Symposia has brought together the patient community, academia and industry to advance advocate-partnered research,
More news about: RARE-X
Jul 28, 2026, 09:40 ET Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026
Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the company's resubmission of its New Drug Application (NDA) for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex
More news about: Saol Therapeutics